Kaiser Permanente Medical Group - Baldwin Park — Baldwin Park, California

Kaiser Permanente Medical Group - Baldwin Park is a clinical research site located in Baldwin Park, California, United States 91706.

Crixeo Clinical Trials Trust Score: 11/100 (FAILING). This profile has not yet been claimed by the site owner.

Kaiser Permanente Medical Group - Baldwin Park has participated in 3 clinical trials with 1 currently active.

Therapeutic areas: Breast Cancer, Gastrinoma, Glucagonoma.

Sponsors: NSABP Foundation Inc, ECOG-ACRIN Cancer Research Group, SWOG Cancer Research Network.

Is this your site?

Is this your site? Claim your profile and control the information sponsors and patients see.

Other research sites in Baldwin Park

Browse all research sites in California · View every site in Baldwin Park

Sponsor Feasibility Report

Trust Score: 11/100. Verification status: Not yet accredited. Patient reviews: 0. Complaints: 0.

Frequently Asked Questions

What is the Trust Score for Kaiser Permanente Medical Group - Baldwin Park?

Kaiser Permanente Medical Group - Baldwin Park has a Crixeo Trust Score of 11/100 (FAILING). Trust Scores reflect trial volume, sponsor diversity, patient reviews, address verification, and accreditation status.

How many clinical trials has Kaiser Permanente Medical Group - Baldwin Park conducted?

Kaiser Permanente Medical Group - Baldwin Park has 3 clinical trials on record, with 1 currently active. Their work covers Breast Cancer, Gastrinoma, Glucagonoma.

Is Kaiser Permanente Medical Group - Baldwin Park accredited by Crixeo Clinical Trials?

Kaiser Permanente Medical Group - Baldwin Park has not yet obtained Crixeo Accreditation. Site owners can claim their profile and apply for accreditation to improve visibility with sponsors and patients.

Can I submit a review or complaint about Kaiser Permanente Medical Group - Baldwin Park?

Yes. Patients and trial participants can submit reviews and file complaints directly on this profile page. All submissions are reviewed before publication.